Figure 1.

Forest plots comparing SGLT2‐Is with non‐SGLT2‐Is for key cardiovascular outcomes. *MACE, major adverse cardiovascular event (this definition may vary among studies); ACM, all‐cause mortality; HHF, hospitalization for heart failure. Please refer to individual studies for details. Meta‐analysis was performed through RevMan 5.3. Crude numbers were extracted from individual studies and computed using the Mantel–Haenszel method (random effect model); therefore, odds ratios of the individual studies may differ compared with published estimates. Where available, data on intention‐to‐treat population at low cardiovascular risk were used. Comparator (non‐SGLT2‐Is) can be represented by all other antidiabetics, insulin or DPP4, depending on studies. The US cohort and OBSERVE‐4D study were the only ones on canagliflozin. Data on the CVD‐REAL Nordic and Swedish cohort studies are derived from the dapagliflozin dataset